ReviewEndocrine connections2021
Growth failure: 'idiopathic' only after a detailed diagnostic evaluation.
Review in Endocrine connections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Global trends in recombinant human growth hormone for the treatment of idiopathic short stature: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Beyond idiopathic short stature: opening a dialogue on nomenclature: Response to the Letter to the Editor: Growth failure of unknown etiology.Archives of endocrinology and metabolism · 2026Article
- Knuckle, Knuckle, Dimple, Dimple: Do Not Miss A Diagnostic Opportunity.Clinical case reports · 2026Article
- Optimising diagnosis in children with short stature: an integrated clinical and NGS approach.Endocrine connections · 2025Article
- Genetic disorders and their association with morbidity and mortality in early preterm small for gestational age infants.American journal of obstetrics and gynecology · 2025Article
- Genetic Findings in Short Turkish Children Born to Consanguineous Parents.Hormone research in paediatrics · 2025Observational
- Current understanding and perspectives on growth and long-acting GH therapy in Japan.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025Review
- Transient Isolated, Idiopathic Growth Hormone Deficiency-A Self-Limiting Pediatric Disease with Male Predominance or a Diagnosis Based on Uncertain Criteria? Lesson from 20 Years' Real-World Experience with Retesting at One Center.International journal of molecular sciences · 2024Article
- Role of genetic investigation in the diagnosis of short stature in a cohort of Italian children.Journal of endocrinological investigation · 2024Article
- Evolving growth hormone deficiency: proof of concept.Frontiers in endocrinology · 2024Article
- Challenges in Pediatric Endocrinology.Children (Basel, Switzerland) · 2023Article
- Late-Onset Isolated Growth Hormone Deficiency.JCEM case reports · 2023Article
- Article
- Novel Insights Into the Genetic Causes of Short Stature in Children.TouchREVIEWS in endocrinology · 2022Review
- Response to Treatment with Recombinant Human Growth Hormone (rhGH) of Short Stature Children Born Too Small for Gestational Age (SGA) in Selected Centres in Poland.Journal of clinical medicine · 2022Article
- Identifying and addressing disparities in the evaluation and treatment of children with growth hormone deficiency.Frontiers in endocrinology · 2022Review
- Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment.Frontiers in endocrinology · 2022Article
- Balanced assessment of growth disorders using clinical, endocrinological, and genetic approaches.Annals of pediatric endocrinology & metabolism · 2021Article
- Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited.Journal of the Endocrine Society · 2021Review
- GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The terms 'idiopathic short stature' (ISS) and 'small for gestational age' (SGA) were first used in the 1970s and 1980s. ISS described non-syndromic short children with undefined aetiology who did not have growth hormone (GH) deficiency, chromosomal defects, chronic illness, dysmorphic features or low birth weight. Despite originating in the pre-molecular era, ISS is still used as a diagnostic label today. The term 'SGA' was adopted by paediatric endocrinologists to describe children born with low birth weight and/or length, some of whom may experience lack of catch-up growth and present with short stature. GH treatment was approved by the FDA for short children born SGA in 2001, and by the EMA in 2003, and for the treatment of ISS in the US, but not Europe, in 2003. These approvals strengthened the terms 'SGA' and 'ISS' as clinical entities. While clinical and hormonal diagnostic techniques remain important, it is the emergence of genetic investigations that have led to numerous molecular discoveries in both ISS and SGA subjects. The primary message of this article is that the labels ISS and SGA are not definitive diagnoses. We propose that the three disciplines of clinical evaluation, hormonal investigation and genetic sequencing should have equal status in the hierarchy of short stature assessments and should complement each other to identify the true pathogenesis in poorly growing patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.